{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:48:40Z","timestamp":1783648120985,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"crossref"}]},{"name":"University of Texas Health San Antonio"},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG20793"],"award-info":[{"award-number":["IG20793"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN 2022ELYS5F"],"award-info":[{"award-number":["PRIN 2022ELYS5F"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25687-w","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:35:49Z","timestamp":1764081349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins"],"prefix":"10.1038","volume":"15","author":[{"given":"Marialuisa","family":"Moccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"25687_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0304-3835(01)00530-4","volume":"169","author":"A Nakagawara","year":"2001","unstructured":"Nakagawara, A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 169, 107\u2013114. https:\/\/doi.org\/10.1016\/s0304-3835(01)00530-4 (2001).","journal-title":"Cancer Lett."},{"key":"25687_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi, A., Le, A. T. & Doebele, R. C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5, 25\u201334. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0765 (2015).","journal-title":"Cancer Discov."},{"key":"25687_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2015.05.013","volume":"365","author":"L Creancier","year":"2015","unstructured":"Creancier, L. et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 365, 107\u2013111. https:\/\/doi.org\/10.1016\/j.canlet.2015.05.013 (2015).","journal-title":"Cancer Lett."},{"key":"25687_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009233","volume":"5","author":"M Santoro","year":"2013","unstructured":"Santoro, M. & Carlomagno, F. Central role of RET in thyroid cancer. Cold Spring Harb. Perspect. Biol. 5, a009233. https:\/\/doi.org\/10.1101\/cshperspect.a009233 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"25687_CR5","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","volume":"24","author":"ES Kheder","year":"2018","unstructured":"Kheder, E. S. & Hong, D. S. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin. Cancer Res. 24, 5807\u20135814. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1156 (2018).","journal-title":"Clin. Cancer Res."},{"key":"25687_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama, Z. T. & Keam, S. J. Entrectinib: First global approval. Drugs 79, 1477\u20131483. https:\/\/doi.org\/10.1007\/s40265-019-01177-y (2019).","journal-title":"Drugs"},{"key":"25687_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","volume":"79","author":"L Scott","year":"2019","unstructured":"Scott, L. Larotrectinib: First global approval. Drugs 79, 201\u2013206. https:\/\/doi.org\/10.1007\/s40265-018-1044-x (2019).","journal-title":"Drugs"},{"key":"25687_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells Jr","year":"2012","unstructured":"Wells, S. A. Jr. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134\u2013141. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040 (2012).","journal-title":"J. Clin. Oncol."},{"key":"25687_CR9","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei, R. et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31, 3639\u20133646. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659 (2013).","journal-title":"J. Clin. Oncol."},{"key":"25687_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah, V. et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8, 836\u2013849. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0338 (2018).","journal-title":"Cancer Discov."},{"key":"25687_CR11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah, V. et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann. Oncol. 29, 1869\u20131876. https:\/\/doi.org\/10.1093\/annonc\/mdy137 (2018).","journal-title":"Ann. Oncol."},{"key":"25687_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth, L. J. et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383, 825\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa2005651 (2020).","journal-title":"N. Engl. J. Med."},{"key":"25687_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor, J. F. et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1\/2 study. Lancet Oncol. 22, 959\u2013969. https:\/\/doi.org\/10.1016\/S1470-2045(21)00247-3 (2021).","journal-title":"Lancet Oncol."},{"key":"25687_CR14","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","volume":"27","author":"D Bradford","year":"2021","unstructured":"Bradford, D. et al. FDA approval summary: Selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin. Cancer Res. 27, 2130\u20132135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3558 (2021).","journal-title":"Clin. Cancer Res."},{"key":"25687_CR15","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","volume":"27","author":"J Kim","year":"2021","unstructured":"Kim, J. et al. FDA approval summary: Pralsetinib for the treatment of lung and thyroid cancers with RET Gene mutations or fusions. Clin. Cancer Res. 27, 5452\u20135456. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0967 (2021).","journal-title":"Clin. Cancer Res."},{"key":"25687_CR16","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.1002\/anie.201501104","volume":"54","author":"B Frett","year":"2015","unstructured":"Frett, B. et al. Fragment-based discovery of a dual pan-RET\/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology. Angew. Chem. Int. Ed. Engl. 54, 8717\u20138721. https:\/\/doi.org\/10.1002\/anie.201501104 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"25687_CR17","doi-asserted-by":"publisher","first-page":"16103","DOI":"10.1038\/s41598-021-95612-4","volume":"11","author":"M Moccia","year":"2021","unstructured":"Moccia, M. et al. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Sci. Rep. 11, 16103. https:\/\/doi.org\/10.1038\/s41598-021-95612-4 (2021).","journal-title":"Sci. Rep."},{"key":"25687_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2021.102114","volume":"67","author":"AJ Tao","year":"2022","unstructured":"Tao, A. J., Gadbois, G. E., Buczynski, S. A. & Ferguson, F. M. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. Curr. Opin. Chem. Biol. 67, 102114. https:\/\/doi.org\/10.1016\/j.cbpa.2021.102114 (2022).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"25687_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114. https:\/\/doi.org\/10.1038\/nrd.2016.211 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"25687_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cbpa.2017.05.016","volume":"39","author":"K Raina","year":"2017","unstructured":"Raina, K. & Crews, C. M. Targeted protein knockdown using small molecule degraders. Curr. Opin. Chem. Biol. 39, 46\u201353. https:\/\/doi.org\/10.1016\/j.cbpa.2017.05.016 (2017).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"25687_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.chembiol.2019.11.014","volume":"27","author":"I You","year":"2020","unstructured":"You, I. et al. Discovery of an AKT degrader with prolonged inhibition of downstream signaling. Cell Chem. Biol. 27, 66-73.e67. https:\/\/doi.org\/10.1016\/j.chembiol.2019.11.014 (2020).","journal-title":"Cell Chem. Biol."},{"key":"25687_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: An RTK case study. Cell Chem. Biol. 25, 67-77.e63. https:\/\/doi.org\/10.1016\/j.chembiol.2017.09.009 (2018).","journal-title":"Cell Chem. Biol."},{"key":"25687_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai, A. C. et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. Engl. 55, 807\u2013810. https:\/\/doi.org\/10.1002\/anie.201507634 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"25687_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763. https:\/\/doi.org\/10.1016\/j.chembiol.2015.05.009 (2015).","journal-title":"Chem. Biol."},{"key":"25687_CR25","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1021\/acs.molpharmaceut.9b00673","volume":"16","author":"B Zhao","year":"2019","unstructured":"Zhao, B. & Burgess, K. TrkC-targeted kinase inhibitors and PROTACs. Mol. Pharm. 16, 4313\u20134318. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00673 (2019).","journal-title":"Mol. Pharm."},{"key":"25687_CR26","doi-asserted-by":"publisher","first-page":"14560","DOI":"10.1021\/acs.jmedchem.0c01947","volume":"63","author":"W Xiang","year":"2020","unstructured":"Xiang, W. & Wang, S. Selectively targeting tropomyosin receptor kinase A (TRKA) via PROTACs. J. Med. Chem. 63, 14560\u201314561. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01947 (2020).","journal-title":"J. Med. Chem."},{"key":"25687_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1021\/acs.jmedchem.4c01424","volume":"68","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Targeting oncogenic RET kinase by simultaneously inhibiting kinase activity and degrading the protein. J. Med. Chem. 68, 81\u201394. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01424 (2025).","journal-title":"J. Med. Chem."},{"key":"25687_CR28","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1021\/acs.jmedchem.4c01889","volume":"68","author":"M Hualong","year":"2025","unstructured":"Hualong, M. et al. Discovery of a selective and orally bioavailable RET degrader with effectiveness in various mutations. J. Med. Chem. 68, 2657\u20132679. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01889 (2025).","journal-title":"J. Med. Chem."},{"key":"25687_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1021\/acs.jmedchem.4c02692","volume":"68","author":"Q Zhang","year":"2025","unstructured":"Zhang, Q. et al. Discovery of an efficacious RET PROTAC degrader with enhanced antiproliferative activity against resistant cancer cells harboring RET solvent-front mutations. J. Med. Chem. 68, 753\u2013775. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02692 (2025).","journal-title":"J. Med. Chem."},{"key":"25687_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809. https:\/\/doi.org\/10.1038\/nsmb.2874 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"25687_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17060744","author":"E Kacin","year":"2025","unstructured":"Kacin, E. & Sewduth, R. N. Molecular design of novel protein-degrading therapeutics agents currently in clinical trial. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics17060744 (2025).","journal-title":"Pharmaceutics"},{"key":"25687_CR32","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.cell.2025.03.036","volume":"188","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. CD36-mediated endocytosis of proteolysis-targeting chimeras. Cell 188, 3219-3237.e3218. https:\/\/doi.org\/10.1016\/j.cell.2025.03.036 (2025).","journal-title":"Cell"},{"key":"25687_CR33","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","volume":"14","author":"Y Dong","year":"2024","unstructured":"Dong, Y. et al. Characteristic roadmap of linker governs the rational design of PROTACs. Acta Pharm. Sin. B 14, 4266\u20134295. https:\/\/doi.org\/10.1016\/j.apsb.2024.04.007 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"25687_CR34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.apsb.2020.02.010","volume":"10","author":"M Hu","year":"2020","unstructured":"Hu, M. et al. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. Acta Pharm. Sin. B 10, 1943\u20131953. https:\/\/doi.org\/10.1016\/j.apsb.2020.02.010 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"25687_CR35","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/bph.15014","volume":"177","author":"K Moreau","year":"2020","unstructured":"Moreau, K. et al. Proteolysis-targeting chimeras in drug development: A safety perspective. Br. J. Pharmacol. 177, 1709\u20131718. https:\/\/doi.org\/10.1111\/bph.15014 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"25687_CR36","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1096\/fj.15-274050","volume":"29","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. A novel effect of thalidomide and its analogs: Suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 29, 4829\u20134839. https:\/\/doi.org\/10.1096\/fj.15-274050 (2015).","journal-title":"FASEB J."},{"key":"25687_CR37","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1093\/emboj\/20.15.4003","volume":"20","author":"T Kawakami","year":"2001","unstructured":"Kawakami, T. et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 20, 4003\u20134012. https:\/\/doi.org\/10.1093\/emboj\/20.15.4003 (2001).","journal-title":"EMBO J."},{"key":"25687_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/416703a","volume":"416","author":"N Zheng","year":"2002","unstructured":"Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703\u2013709. https:\/\/doi.org\/10.1038\/416703a (2002).","journal-title":"Nature"},{"key":"25687_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He, M. et al. PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021). Signal. Transduct. Target Ther. 7, 181. https:\/\/doi.org\/10.1038\/s41392-022-00999-9 (2022).","journal-title":"Signal. Transduct. Target Ther."},{"key":"25687_CR40","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.annonc.2021.02.010","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah, V. et al. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann. Oncol. 32, 817\u2013819. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.010 (2021).","journal-title":"Ann. Oncol."},{"key":"25687_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.onc.1206980","volume":"23","author":"S Peterson","year":"2004","unstructured":"Peterson, S. & Bogenmann, E. The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 23, 213\u2013225. https:\/\/doi.org\/10.1038\/sj.onc.1206980 (2004).","journal-title":"Oncogene"},{"key":"25687_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3892\/or.2020.7583","volume":"44","author":"LH Tetri","year":"2020","unstructured":"Tetri, L. H. et al. RET receptor expression and interaction with TRK receptors in neuroblastomas. Oncol. Rep. 44, 263\u2013272. https:\/\/doi.org\/10.3892\/or.2020.7583 (2020).","journal-title":"Oncol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25687-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25687-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:35:49Z","timestamp":1764081349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25687-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25687"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25687-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal manipulation was performed in accordance with ARRIVE guidelines and with the relevant guidelines and regulations (reference number:683\/2024-PR) approved by the Italian Ministry of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41770"}}